Menopause Practice Questions

Q: What is the investigation of choice in postmenopausal bleeding?

Ultrasound. ***Ultrasound*** - An initial **transvaginal ultrasound** is the investigation of choice to assess the endometrial thickness in postmenopausal bleeding. An endometrial thickness of >4-5mm often warrants further investigation. - It helps in **ruling out endometrial pathologies** like hyperplasia, polyps, or carcinoma. *PAP smear* - A **PAP smear** is a screening test for cervical cancer, not typically used to investigate postmenopausal bleeding originating from the uterus. - While it can detect some endometrial cells, it is **not sensitive** or specific enough to diagnose the cause of postmenopausal bleeding. *Laparoscopy* - **Laparoscopy** is a surgical procedure used to visualize pelvic organs and is generally employed for diagnosing and treating conditions like endometriosis, ovarian cysts, or ectopic pregnancies. - It is **not the initial investigation** for postmenopausal bleeding and is too invasive for primary diagnosis unless other methods have failed or a specific pathology is suspected. *Fractional curettage* - **Fractional curettage** involves scraping the lining of the cervix and uterus to obtain tissue samples for histological examination. - While it can be diagnostic for endometrial pathology, it is typically performed **after an initial ultrasound** has identified increased endometrial thickness or other suspicious findings, and less commonly as a standalone initial investigation.

Q: Which of the following statements about the postmenopausal state is false?

Low LH. ***Low LH*** - This statement is **FALSE** because **LH (luteinizing hormone) levels are markedly elevated** in postmenopausal women. - The drop in ovarian estrogen production removes the **negative feedback** on the pituitary, leading to **increased LH and FSH secretion**. - Both gonadotropins (LH and FSH) are characteristically **high in postmenopause**. *High FSH* - This statement is true; **FSH (follicle-stimulating hormone) levels are markedly elevated** in postmenopausal women. - The elevated FSH is a direct consequence of the **lack of negative feedback** from inhibin and estrogen produced by the ovaries. *Low estrogen* - This statement is true; **estrogen levels plummet significantly** after menopause due to the **cessation of ovarian follicular activity**. - This **estrogen deficiency** is responsible for many postmenopausal symptoms, such as hot flashes, vaginal atrophy, and bone loss. *High androgen* - While androgens are still produced by the adrenal glands and ovaries postmenopause, their **absolute levels also decline with age**. - The statement is somewhat ambiguous, but androgens do **not increase** in absolute terms; rather, the **estrogen-to-androgen ratio changes** because estrogen falls more dramatically.

Q: Which of the following hormones increases during the postmenopausal period?

FSH. ***FSH*** - In **postmenopausal women**, the ovaries no longer produce significant amounts of **estrogen** and **progesterone**. - This lack of negative feedback on the **hypothalamus** and **pituitary gland** leads to a compensatory increase in **gonadotropin-releasing hormone (GnRH)**, which, in turn, stimulates the pituitary to produce more **FSH** and to a lesser extent, **LH**. *Progesterone* - **Progesterone levels decline** significantly after menopause as ovulation ceases. - The **corpus luteum**, which produces progesterone after ovulation, is no longer formed. *Estrogen* - **Estrogen levels decline dramatically** after menopause due to the cessation of ovarian follicular activity. - This decrease in estrogen is responsible for many menopausal symptoms, such as **hot flashes** and **vaginal dryness**. *Androgens* - While **ovarian androgen production** decreases, **adrenal androgen production** (e.g., **DHEA** and **androstenedione**) continues. - However, overall **androgen levels tend to decrease slightly** but not as dramatically as estrogen or progesterone, and they do not increase.

Q: Which of the following statements about the benefits of hormone replacement therapy is incorrect?

Reduction in colorectal cancer (20%). ***Reduction in colorectal cancer (20%)*** - While the **Women's Health Initiative (WHI)** study demonstrated a reduction in colorectal cancer incidence with combined estrogen-progestin therapy, this is **NOT considered an established or recommended benefit** of HRT. - The evidence is **inconsistent** across different studies, and importantly, colorectal cancers detected in HRT users were found at **more advanced stages**. - The **risks of HRT** (increased breast cancer, cardiovascular events, venous thromboembolism) significantly **outweigh** this uncertain benefit. - This is **NOT listed as an indication** for HRT in clinical guidelines, making this statement misleading when discussing "benefits" of HRT. *Improvement in urogenital atrophy* - **Estrogen deficiency** during menopause causes **vaginal and urethral atrophy**, leading to **dyspareunia, vaginal dryness, urgency**, and **recurrent UTIs**. - **Estrogen replacement therapy** (especially local vaginal estrogen) is **highly effective** in reversing urogenital atrophy. - This is a **well-established, FDA-approved indication** for HRT. *Increase in bone mineral density (2-5%)* - **Estrogen inhibits osteoclast activity** and promotes bone formation, playing a crucial role in maintaining **bone mineral density**. - HRT produces a **significant increase in BMD (2-5%)**, helping to **prevent osteoporosis** and reduce fracture risk in postmenopausal women. - This is a **proven benefit** and approved indication for HRT, particularly for women at high risk of osteoporosis. *40-50% improvement in vasomotor symptoms* - **Vasomotor symptoms** (hot flashes and night sweats) are the **hallmark of menopause**, caused by **estrogen deficiency**. - **HRT is the most effective treatment**, reducing frequency and severity by **40-50%** or more. - This is the **primary and most important indication** for initiating HRT in symptomatic menopausal women.

Q: Most useful investigation in a 55-year-old postmenopausal woman with diabetes mellitus and hypertension who has presented with postmenopausal bleeding is:

Endometrial biopsy. ***Endometrial biopsy*** - This is the **most crucial investigation** for postmenopausal bleeding to rule out **endometrial cancer** or **hyperplasia**, especially in a patient with risk factors like diabetes and hypertension. - An endometrial biopsy directly samples the **uterine lining** for histological examination, providing a definitive diagnosis of any abnormal tissue changes. *Pap test* - A Pap test, or **Papanicolaou test**, primarily screens for **cervical cancer** by examining cells from the cervix. - It is **not effective** for detecting uterine (endometrial) abnormalities or cancer, which is the main concern with postmenopausal bleeding. *Transvaginal ultrasound examination* - While useful for assessing **endometrial thickness** and identifying structural abnormalities like polyps or fibroids, it is **not diagnostic** on its own. - An abnormal ultrasound finding, such as a thickened endometrium (usually >4-5mm in postmenopausal women), would typically prompt an endometrial biopsy for definitive diagnosis. *CA-125 blood test* - **CA-125** is a tumor marker primarily used for monitoring the response to treatment in **ovarian cancer** and can be elevated in other conditions like endometriosis or fibroids. - It is **not a screening tool** for endometrial cancer and is **not specific or sensitive enough** to be the primary investigation for postmenopausal bleeding.

Question 1

What is the investigation of choice in postmenopausal bleeding?

Accepted Answer

Ultrasound

Answer

PAP smear

Answer

Laparoscopy

Answer

Fractional curettage

Question 2

Which of the following statements about the postmenopausal state is false?

Accepted Answer

Low LH

Answer

High FSH

Answer

Low estrogen

Answer

High androgen

Question 3

Which of the following hormones increases during the postmenopausal period?

Accepted Answer

FSH

Answer

Progesterone

Answer

Estrogen

Answer

Androgens

Question 4

Which of the following statements about the benefits of hormone replacement therapy is incorrect?

Accepted Answer

Reduction in colorectal cancer (20%)

Answer

Improvement in urogenital atrophy

Answer

Increase in bone mineral density (2-5%)

Answer

40 - 50% improvement in vasomotor symptoms

Question 5

Most useful investigation in a 55-year-old postmenopausal woman with diabetes mellitus and hypertension who has presented with postmenopausal bleeding is:

Accepted Answer

Endometrial biopsy

Answer

Pap test

Answer

Transvaginal ultrasound examination

Answer

CA-125 blood test

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?